2022 Symposium Supporters

Y-mAbs is a late-stage clinical, global biopharmaceutical company specializing in developing antibody-based products to treat challenging pediatric cancers, and ultimately adult patients.

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative products to patients for over a century.

Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing products to patients that they may not otherwise be able to access.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.

Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients.

We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

EUSA Pharma is a dynamic, global biopharmaceuticalcompany focused on oncology and rare disease, continuously striving to confront gaps in patient care. As a global biopharmaceutical company, EUSA Pharma is committed to deliver solutions that can have a meaningful effect on life, helping patients across a range of therapy areas. 

Founded in 2015, we are continuously looking for newopportunities to confront current gaps in patient care. Our ambition and entrepreneurial culture drive us to explore, acquire and in-license products that we believe can bring about real change for patients. 

The symposium was supported by a medical educational grant by EUSA Pharma.

United Therapeutics Corporation is abiotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and
life-threatening conditions. As a group, we are relentless in our pursuit of
“medicines for life” and continue to research and develop treatments for
cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.